Transcription Factor Forkhead Box Protein 3 (FOXP3) as a Prognostic Indicator for Postoperative Outcomes in Patients with Breast Cancer: Establishment of a Prognostic Nomogram.

IF 3.3 4区医学 Q2 ONCOLOGY

Breast Cancer : Targets and Therapy Pub Date : 2024-10-21 eCollection Date: 2024-01-01 DOI:10.2147/BCTT.S484055

Chunlei Tan, Jinling Xu, Shiyuan Zhang, Shuqiang Liu, Xiaotian Yang, Danping Wu, Boqian Yu, Yuanxi Huang

{"title":"Transcription Factor Forkhead Box Protein 3 (FOXP3) as a Prognostic Indicator for Postoperative Outcomes in Patients with Breast Cancer: Establishment of a Prognostic Nomogram.","authors":"Chunlei Tan, Jinling Xu, Shiyuan Zhang, Shuqiang Liu, Xiaotian Yang, Danping Wu, Boqian Yu, Yuanxi Huang","doi":"10.2147/BCTT.S484055","DOIUrl":null,"url":null,"abstract":"Purpose: The current investigation is to assess FOXP3 expression in breast cancer patients and evaluate the predictive significance of FOXP3.Patients and methods: A cohort of 313 cases between January 2015 and November 2015 were enrolled this research. Immunohistochemistry (IHC) assay was utilized to detect the expression levels of FOXP3 in primary breast carcinoma specimens. These patients were separated into two groups by semiquantitative scoring approach. Chi-square test and Fisher's exact test were conducted to investigate the correlations between FOXP3 expression in tumors and clinicopathological variables. Kaplan-Meier method and Log rank test were utilized to generate survival curves for disease-free survival (DFS) and overall survival (OS). The independent factors were examined using Cox regression analysis. Nomogram models were created for assessing DFS and OS rates.Results: Depending on the levels of FOXP3 expression in tumors, these patients were categorized into two groups: low FOXP3 expression (174 cases) and high FOXP3 expression (139 cases). The patients exhibiting low levels of FOXP3 expression in tumors demonstrated a longer survival duration contrasted with those with high expression (DFS: 88.75 vs 65.87 months, χ2=36.1100, P<0.0001; OS: 89.70 vs 78.37 months, χ2=32.4900, P<0.0001). Multivariate analysis revealed that FOXP3 was a significant prognostic factor [DFS: hazard ratio (HR): 2.822, 95% CI: 1.595-4.992, P<0.0001; OS: HR: 3.232, 95% CI: 1.812-5.763, P<0.0001]. The good predictive clinical utility of FOXP3-based nomograms within the threshold probability range for different survival rates was demonstrated by calibration curve and decision curve analyses.Conclusion: FOXP3 expression serves as a crucial prognostic indicator in breast cancer patients, and may aid preoperative evaluation in clinical practice.","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"16 ","pages":"705-723"},"PeriodicalIF":3.3000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11505482/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer : Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/BCTT.S484055","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The current investigation is to assess FOXP3 expression in breast cancer patients and evaluate the predictive significance of FOXP3.

Patients and methods: A cohort of 313 cases between January 2015 and November 2015 were enrolled this research. Immunohistochemistry (IHC) assay was utilized to detect the expression levels of FOXP3 in primary breast carcinoma specimens. These patients were separated into two groups by semiquantitative scoring approach. Chi-square test and Fisher's exact test were conducted to investigate the correlations between FOXP3 expression in tumors and clinicopathological variables. Kaplan-Meier method and Log rank test were utilized to generate survival curves for disease-free survival (DFS) and overall survival (OS). The independent factors were examined using Cox regression analysis. Nomogram models were created for assessing DFS and OS rates.

Results: Depending on the levels of FOXP3 expression in tumors, these patients were categorized into two groups: low FOXP3 expression (174 cases) and high FOXP3 expression (139 cases). The patients exhibiting low levels of FOXP3 expression in tumors demonstrated a longer survival duration contrasted with those with high expression (DFS: 88.75 vs 65.87 months, χ²=36.1100, P<0.0001; OS: 89.70 vs 78.37 months, χ²=32.4900, P<0.0001). Multivariate analysis revealed that FOXP3 was a significant prognostic factor [DFS: hazard ratio (HR): 2.822, 95% CI: 1.595-4.992, P<0.0001; OS: HR: 3.232, 95% CI: 1.812-5.763, P<0.0001]. The good predictive clinical utility of FOXP3-based nomograms within the threshold probability range for different survival rates was demonstrated by calibration curve and decision curve analyses.

Conclusion: FOXP3 expression serves as a crucial prognostic indicator in breast cancer patients, and may aid preoperative evaluation in clinical practice.

查看原文本刊更多论文

转录因子叉头盒蛋白 3 (FOXP3) 作为乳腺癌患者术后结果的预后指标：建立预后提名图。

目的：本研究旨在评估FOXP3在乳腺癌患者中的表达，并评估FOXP3的预测意义：本次研究共纳入2015年1月至2015年11月期间的313例病例。利用免疫组化（IHC）检测原发性乳腺癌标本中 FOXP3 的表达水平。通过半定量评分法将这些患者分为两组。采用卡普兰-梅耶法（Kaplan-Meier method）和费雪精确检验（Fisher's exact test）研究肿瘤中 FOXP3 表达与临床病理变量之间的相关性。利用 Kaplan-Meier 法和对数秩检验生成无病生存期（DFS）和总生存期（OS）的生存曲线。利用 Cox 回归分析对独立因素进行了研究。为评估无病生存率和总生存率建立了提名图模型：根据肿瘤中 FOXP3 的表达水平，这些患者被分为两组：FOXP3 低表达组（174 例）和 FOXP3 高表达组（139 例）。与高表达组相比，肿瘤中 FOXP3 低表达组患者的生存期更长（DFS：88.75 个月 vs 65.87 个月，χ2=36.1100，P2=32.4900，PConclusion：FOXP3 表达是乳腺癌患者预后的一个重要指标，在临床实践中可能有助于术前评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊